AlphAIAlphAI — Financial news for AI agents
investing.com$PLSE

Mizuho raises Pulse Biosciences stock price target on trial progress

Mizuho raised its price target for Pulse Biosciences (PLSE) to $65 from $55, citing faster-than-expected trial progress. The stock is up 287% YTD. Q3 2026 saw a wider-than-expected loss of $0.32 per share, but revenue increased to $395,000. The company has $189.2M in cash. Analysts maintain a Strong Buy consensus with targets ranging from $55 to $80.

Original reporting
investing.com
Published Nov 6, 2026, 11:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 11:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PLSE
Bullish
high confidence
Mentioned
$PLSE
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PLSEBullishMed
01

Why it matters

The new target may attract buying interest, though the loss could temper enthusiasm.

02

Market read

The article provides fresh analyst guidance and earnings data that could influence short-term trading decisions on PLSE.

03

What to watch

Potential regulatory delays or trial setbacks not yet disclosed.

Relevance 6/10Novelty 7/10Timing: today

Background

Pulse Biosciences reported Q3 2026 results with a slight earnings miss but raised its price target based on trial enrollment progress.

Company-level read

Ticker impact

$PLSEBullishHigh confidence
Context

Mizuho raised its price target on Pulse Biosciences to $65 and reported a Q3 loss of $0.32 per share.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Analyst upgrade and higher target provide a fresh catalyst that can lift the stock in the near term.

Market effects

Sector

Positive for the biotech/medical device sector as the target raise may signal confidence in trial progress.

Regional

Limited to US-listed biotech investors.

Global

Minor, confined to niche investors.

Counterpoint

What could challenge this read

The earnings miss and modest cash burn could outweigh the target raise, keeping downside risk.

Key entities

  • company
    Pulse Biosciences

    NASDAQ-listed biotech developing nanotechnology therapies.

  • analyst
    Mizuho

    Equity research firm that raised the price target.

Read at source← All news

Related articles

$PLSEMed

Pulse Bio (PLSE) Q3 2026 Earnings Call Transcript

Pulse Bio (PLSE) reported Q3 2026 earnings, highlighting completion of Nano-Pulse AF study enrollment ahead of schedule with 169 evaluable patients. The company has $189M in cash, supporting operations for two years. Pulse Bio's nPulse cardiac catheter system showed rapid adoption and positive feedback from physicians, with potential transformative impact. The company expects final data in Q3 2027 and CE Mark approval in Q4 2027.

finance.yahoo.com
$PLSEMedAI 8/10

Pulse Biosciences: 86% Achieve Thyroid Nodule Reduction Endpoint at Six Months

Pulse Biosciences reported 86% of patients in its PRECISE-BTN study achieved at least 50% thyroid nodule volume reduction at six months, with a median reduction of 72%. Quality of life scores improved 78%, and 82% of patients saw resolution of neck pressure or fullness. No serious adverse events were reported. The company plans to release more data as follow-up continues.

tradingview.com
$PLSEMedAI 8/10

Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting 86% of patients evaluated achieved at least 50% nodule volume reduction at six months after a single nonthermal nsPFA treatm

SEC EDGAR 8-K
$PLSEMedAI 8/10

Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results Completed enrollment of NANOPULSE-AF US IDE pivotal study for treatment of AF with nPulse Cardiac Catheter System Ended the quarter with $189 million of cash, cash equivalents, and ma

SEC EDGAR 8-K
$PLSEMedAI 8/10

How Trial Enrollment Completion At Pulse Biosciences (PLSE) Has Changed Its Investment Story

Pulse Biosciences (PLSE) completed enrollment for its NANOPULSE-AF study, meeting its target of 164 patients across 15 sites. The study aims to assess the safety and effectiveness of its nPulse Cardiac Catheter System for drug-resistant atrial fibrillation. Analysts forecast revenue of $38.3M and earnings of $4.8M by 2029, with significant growth and earnings swing expected. The trial's outcomes will influence regulatory, reimbursement, and commercialization decisions.

simplywall.st